Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NACC1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral, Intraperitoneal
01
Overview
NACC1 siRNA is a research-grade small interfering RNA (siRNA) tool compound designed to silence the NACC1 gene (Nucleus Accumbens Associated Protein 1) through RNA interference (RNAi). By targeting and degrading NACC1 mRNA, it suppresses the expression of the NAC1 protein, a transcriptional repressor involved in tumor growth, metastasis, and drug resistance. In preclinical studies, NACC1 siRNA has been utilized to investigate the role of the NR2F6-NACC1-NOTCH3 axis in malignancies such as endometrial cancer and urothelial carcinoma. Inhibition of NACC1 via siRNA has been shown to suppress cell proliferation and induce cell cycle arrest at the G0/G1 phase. It is primarily available as a laboratory reagent from life science suppliers and is not currently a clinical-stage therapeutic asset.
- Other names
- NAC1 siRNANAC-1 siRNANAC 1 siRNANucleus accumbens-associated protein 1 siRNA
02
Targets
NACC1 (Nucleus accumbens-associated protein 1)
Beyond the preview
Go deeper on NACC1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NACC1 siRNA.